Compare Incyte Corporation (INCY) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while KraneShares Electric Vehicles and Future Mobility trades at $27.86 (market cap $72.36M). The key difference: Incyte Corporation is far larger — about 315.8× KraneShares Electric Vehicles and Future Mobility's market cap, and Incyte Corporation is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and KraneShares Electric Vehicles and Future Mobility for 46 Days on average.
| INCY | KARS | |
|---|---|---|
Market Cap | $22.85B | $72.36M |
Volume | 1,927,029 | 5,034 |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $38.01 |
52-Week Low | $83.80 | $27.25 |
Typical Hold Time | 33 Days | 46 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
KARS trades at $27.86, up 0.25% with a bearish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 54.12 and 45.15, while ADX indicates mixed trend strength. Support and resistance cluster around $28-$29 levels, suggesting potential consolidation. Recent news highlights mixed EV market trends with US sales lagging while global demand grows.
The outlook remains cautious given bearish technical signals and mixed EV market dynamics. Investment opportunity exists in global EV growth trends, but risks include US market headwinds and regulatory uncertainty. Stock performance may depend on company-specific execution amid evolving industry conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
